Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 8/20 | 0.46 |
| ▸ | ABL1 | P00519 | 6/20 | 0.46 |
| ▸ | HCK | P08631 | 5/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.43 |
| ▸ | PRKDC | P78527 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.40 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21364711 | 0.85 | MAP4K4 (0.52) | BTKSRCABL1HCKPIK3CD | |
| SCHEMBL149528 | 0.85 | KDR (0.52) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL21772444 | 0.83 | MAPK1 (0.42) | BTKSRCABL1HCKPIK3CD | |
| SCHEMBL19414293 | 0.82 | ALDH1A1 (0.50) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL13717931 | 0.81 | SRC (0.48) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL18235468 | 0.81 | KDR (0.49) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL12713498 | 0.81 | PIK3CD (0.50) | BTKSRCABL1PIK3CDPIK3CA | |
| SCHEMBL19414292 | 0.80 | SRC (0.42) | BTKSRCABL1HCKPIK3CB | |
| SCHEMBL20093481 | 0.80 | KMO (0.46) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL13717800 | 0.80 | CSNK1E (0.45) | SRCABL1HCKPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | BTK 345/4885SRC 202/4885ABL1 329/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | BTK 369/4885SRC 254/4885ABL1 464/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | BTK 346/4885SRC 285/4885ABL1 334/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | BTK 204/4885SRC 90/4885ABL1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.